Skip to main content

Aflatoxin, Hepatitis and Worldwide Liver Cancer Risks

  • Chapter

Part of the Advances in Experimental Medicine and Biology book series (AEMB,volume 504)

Abstract

Aflatoxins are among the most potent mutagenic and carcinogenic substances known. Differential potency of aflatoxin among species can be partially attributed to differences in metabolism; however, current information on competing aspects of metabolic activation and detoxification of aflatoxin in various species does not identify an adequate animal model for humans. Risk of liver cancer is influenced by a number of factors, most notably carriage of hepatitis B virus as determined by the presence in serum of the hepatitis B surface antigen (HBsAg+ or HBsAg-). About 50 to 100% of liver cancer cases are estimated to be associated with persistent infection of hepatitis B (or C) virus. The potency of aflatoxin in HBsAg+ individuals is substantially higher (about a factor of 30) than the potency in HBsAg-individuals. Thus, reduction of the intake of aflatoxins in populations with a high prevalence of HBsAg+ individuals will have greater impact on reducing liver cancer rates than reductions in populations with a low prevalence of HbsAg+ individuals. The present analysis suggests that vaccination against hepatitis B (or protection against hepatits C), which reduces prevalence of carriers, would reduce the potency of the aflatoxins in vaccinated populations and reduce liver cancer risk.

Keywords

  • Liver Cancer
  • Pool Urine Sample
  • Aflatoxin Exposure
  • Liver Cancer Case
  • Adequate Animal Model

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alter, M.J, 1996, Epidemiology of hepatitis C.Eur. J. Gastroenterol. Hepatol.8:319.

    CrossRef  CAS  Google Scholar 

  • Bosch, F.X., Ribes, J., and Borras, J., 1999, Epidemiology of primary liver cancer in:Seminars in Liver Disease19(3):271.

    CrossRef  CAS  Google Scholar 

  • Chi, W.J., Doong, S.-L., Lin-Shiau, S.-Y., Boone, C.W., Kellloff, G.J., and Lin, J., 1998, Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein.Carcinogenesis19(12): 2133.

    CrossRef  CAS  Google Scholar 

  • Deurric, S., Poynard, T., Buffet, L., and Valleron, A.-J., 1998, Trends in primary liver cancer.The Lancet351:215.

    Google Scholar 

  • El-Serag, H.B. and Mason, A.C., 2000, Rsisk factors for the rising rates of hepatocellular carcinoma in the United States.Gastroenterol. 118(4): Suppl 2. 3792.

    Google Scholar 

  • Gay, N.J., and Edmonds, W.J., 1998, Developed countries could pay for hepatitis B vaccination in developing countries.Brit. Med. J.316:1457.

    CrossRef  CAS  Google Scholar 

  • Hoofnagle, J.H., 1997, Hepatitis C: the clinical spectrum of disease.Hepatol. 26:155.

    CrossRef  Google Scholar 

  • IARC, 1994, Hepatitis viruses, Monographs on the evaluation of carcinogenic risks to humans. IARC Sci. Publ. 59. Lyon, France.

    Google Scholar 

  • JECFA, 1998, Aflatoxins. Safety evaluation of certain food additives and contaminants. (The forty-ninth meeting of the Joint FAO/WHO Expert Committee on Food Additives.). WHO Food Additives Series, no. 40. World Health Organization, Geneva 1998. pp 359–468.

    Google Scholar 

  • Kensler, T.W., He, X., Otieno, M., Egner, P.A., Jacobson, L.P., Chen, B., Wang, J.S., Zhu, Y.R., Zhang, B.C., 1998, Oltipraz chemoprevention trial in Qidong, People’s Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.Cancer Epidemiol. Biomarkers Prey.7:127.

    CAS  Google Scholar 

  • Lee, M.-S., Kim, D.-H., Kim, H., Lee, H.-S., Kim, C.-Y., Park, T.-S., Yoo, K.-Y., Park, B.-J., and Alm, Y-O., 1998, Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea.Int. J of Epidem.27:316.

    CrossRef  CAS  Google Scholar 

  • Parkin, D.M., 1998, The global burden of cancerSemin. Cancer Biol.8:219.

    CrossRef  CAS  Google Scholar 

  • Sun, Z., Lu, P., Gail, M.H., Pee, D., Zhang Q Ming, L., Wang, J., Wu, Y., Liu, G., Wu, Y., and Zhu, Y., 1999, Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite MI.Hepatol.30:379.

    CrossRef  CAS  Google Scholar 

  • Wang, J.S., Qian, G.S., Zarba, A., He, X., Zhu, Y.R., Zhang, B.C., Jacobson, L., Gange, S.J., Munoz, A., Kensler, T.W., 1996, Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen positive and antigen-negative residents of Daxin, Qidong County, People’s Republic of China.Cancer Epidemiol. Biomarkers Prey.5:253–261.

    CAS  Google Scholar 

  • Wang, J.S., Shen, X., He, X., Zhu, B.C., Zhang, B.C., Wang, J.B., Qian, G.S., Kuang, S.Y., Zarba, A., Egner, P.A., 1999, Protective alterations in phase 1 and 2 metabolism of aflatoxin B I by oltipraz in residents of Qidong, People’s Republic of China.JNCI91:347–354.

    CrossRef  CAS  Google Scholar 

  • Wild, C.P., and Hall, A.J., 2000, Primary prevention of hepatocellular carcinoma in developing countries.Mut. Res.462:381.

    CrossRef  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Henry, S.H., Bosch, F.X., Bowers, J.C. (2002). Aflatoxin, Hepatitis and Worldwide Liver Cancer Risks. In: DeVries, J.W., Trucksess, M.W., Jackson, L.S. (eds) Mycotoxins and Food Safety. Advances in Experimental Medicine and Biology, vol 504. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0629-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0629-4_24

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5166-5

  • Online ISBN: 978-1-4615-0629-4

  • eBook Packages: Springer Book Archive